{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:59:40Z","timestamp":1786982380476,"version":"build-2736575974"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2025,9,18]],"date-time":"2025-09-18T00:00:00Z","timestamp":1758153600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,9,18]],"date-time":"2025-09-18T00:00:00Z","timestamp":1758153600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100008322","name":"CSL Behring","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008322","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1007\/s12325-025-03336-y","type":"journal-article","created":{"date-parts":[[2025,9,18]],"date-time":"2025-09-18T06:29:30Z","timestamp":1758176970000},"page":"5696-5707","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Comparing Real-World Outcomes of Prophylaxis with Extended Half-life Factor\u00a0IX (rIX-FP vs. rFIXFc and N9-GP) for Haemophilia\u00a0B: An Analysis of Medical Chart Data from Germany"],"prefix":"10.1007","volume":"42","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6434-6244","authenticated-orcid":false,"given":"Martin","family":"Olivieri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1677-3839","authenticated-orcid":false,"given":"Songkai","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Radovan","family":"Tomic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8210-9277","authenticated-orcid":false,"given":"Thomas","family":"Linhoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-7388-2013","authenticated-orcid":false,"given":"Douglass","family":"Drelich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalie","family":"Jakobs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4506-0061","authenticated-orcid":false,"given":"Wolfgang","family":"Miesbach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,18]]},"reference":[{"issue":"Suppl 6","key":"3336_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/hae.14046","volume":"26","author":"A Srivastava","year":"2020","unstructured":"Srivastava A, Santagostino E, Dougall A, et al. WFH guidelines for the management of hemophilia, 3rd edition. Haemophilia. 2020;26(Suppl 6):1\u2013158.","journal-title":"Haemophilia"},{"issue":"8","key":"3336_CR2","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1080\/17474086.2018.1489719","volume":"11","author":"G Castaman","year":"2018","unstructured":"Castaman G. The benefits of prophylaxis in patients with hemophilia\u00a0B. Expert Rev Hematol. 2018;11(8):673\u201383.","journal-title":"Expert Rev Hematol"},{"issue":"12","key":"3336_CR3","doi-asserted-by":"publisher","first-page":"2405","DOI":"10.1182\/blood-2012-05-429688","volume":"120","author":"E Santagostino","year":"2012","unstructured":"Santagostino E, Negrier C, Klamroth R, et al. Safety and pharmacokinetics of a novel recombinant fusion protein linking coagulation factor\u00a0IX with albumin (rIX-FP) in hemophilia\u00a0B patients. Blood. 2012;120(12):2405\u201311.","journal-title":"Blood"},{"issue":"4","key":"3336_CR4","first-page":"634","volume":"102","author":"HJ Metzner","year":"2009","unstructured":"Metzner HJ, Weimer T, Kronthaler U, Lang W, Schulte S. Genetic fusion to albumin improves the pharmacokinetic properties of factor\u00a0IX. Thromb Haemost. 2009;102(4):634\u201344.","journal-title":"Thromb Haemost"},{"issue":"24","key":"3336_CR5","doi-asserted-by":"publisher","first-page":"2313","DOI":"10.1056\/NEJMoa1305074","volume":"369","author":"JS Powell","year":"2013","unstructured":"Powell JS, Pasi KJ, Ragni MV, et al. Phase\u00a03 study of recombinant factor\u00a0IX Fc fusion protein in hemophilia\u00a0B. N Engl J Med. 2013;369(24):2313\u201323.","journal-title":"N Engl J Med"},{"issue":"26","key":"3336_CR6","doi-asserted-by":"publisher","first-page":"3880","DOI":"10.1182\/blood-2014-05-573055","volume":"124","author":"PW Collins","year":"2014","unstructured":"Collins PW, Young G, Knobe K, et al. Recombinant long-acting glycopegylated factor\u00a0IX in hemophilia\u00a0B: a multinational randomized phase\u00a03 trial. Blood. 2014;124(26):3880\u20136.","journal-title":"Blood"},{"issue":"14","key":"3336_CR7","doi-asserted-by":"publisher","first-page":"1761","DOI":"10.1182\/blood-2015-09-669234","volume":"127","author":"E Santagostino","year":"2016","unstructured":"Santagostino E, Martinowitz U, Lissitchkov T, et al. Long-acting recombinant coagulation factor\u00a0IX albumin fusion protein (rIX-FP) in hemophilia\u00a0B: results of a phase\u00a03 trial. Blood. 2016;127(14):1761\u20139.","journal-title":"Blood"},{"issue":"1","key":"3336_CR8","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1080\/03007995.2019.1662675","volume":"36","author":"J Oldenburg","year":"2020","unstructured":"Oldenburg J, Yan S, Maro G, Krishnarajah G, Tiede A. Assessing bleeding rates, related clinical impact and factor utilization in German hemophilia\u00a0B patients treated with extended half-life rIX-FP compared to prior drug therapy. Curr Med Res Opin. 2020;36(1):9\u201315.","journal-title":"Curr Med Res Opin"},{"issue":"1","key":"3336_CR9","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1111\/hae.14689","volume":"29","author":"A Tagliaferri","year":"2023","unstructured":"Tagliaferri A, Molinari AC, Peyvandi F, et al. IDEAL study: a real-world assessment of pattern of use and clinical outcomes with recombinant coagulation factor\u00a0IX albumin fusion protein (rIX-FP) in patients with haemophilia\u00a0B in Italy. Haemophilia. 2023;29(1):135\u201344.","journal-title":"Haemophilia"},{"issue":"5","key":"3336_CR10","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1111\/ejh.14168","volume":"112","author":"P Giordano","year":"2024","unstructured":"Giordano P, Pollio B, Sottilotta G, et al. Pattern of use and clinical outcomes with rIX-FP in pediatric\/adolescent patients with haemophilia\u00a0B in Italy: results from IDEAL real-world study. Eur J Haematol. 2024;112(5):765\u201375.","journal-title":"Eur J Haematol"},{"issue":"6","key":"3336_CR11","doi-asserted-by":"publisher","first-page":"2988","DOI":"10.1007\/s12325-020-01300-6","volume":"37","author":"C Hermans","year":"2020","unstructured":"Hermans C, Marino R, Lambert C, et al. Real-world utilisation and bleed rates in patients with haemophilia\u00a0B who switched to recombinant factor\u00a0IX fusion protein (rIX-FP): a retrospective international analysis. Adv Ther. 2020;37(6):2988\u201398.","journal-title":"Adv Ther"},{"issue":"5","key":"3336_CR12","doi-asserted-by":"publisher","DOI":"10.1016\/j.rpth.2024.102482","volume":"8","author":"C Bidlingmaier","year":"2024","unstructured":"Bidlingmaier C, Heller C, Langer F, et al. Real-world usage and effectiveness of recombinant factor VIII\/factor\u00a0IX Fc in hemophilia A\/B: final data from the 24-month, prospective, noninterventional PREVENT study in Germany. Res Pract Thromb Haemost. 2024;8(5):102482.","journal-title":"Res Pract Thromb Haemost"},{"issue":"3","key":"3336_CR13","doi-asserted-by":"publisher","DOI":"10.1002\/rth2.12661","volume":"6","author":"D Matino","year":"2022","unstructured":"Matino D, Iorio A, Keepanasseril A, et al. Switching to nonacog beta pegol in hemophilia\u00a0B: outcomes from a Canadian real-world, multicenter, retrospective study. Res Pract Thromb Haemost. 2022;6(3):e12661.","journal-title":"Res Pract Thromb Haemost"},{"key":"3336_CR14","unstructured":"CSL Behring. IDELVION (albutrepenonacog alfa) Summary of Product Characteristics. 2023. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/idelvion-epar-product-information_en.pdf. Accessed 12 June 2024."},{"issue":"5","key":"3336_CR15","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1111\/jth.14778","volume":"18","author":"ME Mancuso","year":"2020","unstructured":"Mancuso ME, Lubetsky A, Pan-Petesch B, et al. Long-term safety and efficacy of rIX-FP prophylaxis with extended dosing intervals up to 21\u00a0days in adults\/adolescents with hemophilia\u00a0B. J Thromb Haemost. 2020;18(5):1065\u201374.","journal-title":"J Thromb Haemost"},{"issue":"4","key":"3336_CR16","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1055\/s-0040-1705116","volume":"120","author":"G Kenet","year":"2020","unstructured":"Kenet G, Chambost H, Male C, et al. Long-term safety and efficacy of recombinant coagulation factor\u00a0IX albumin fusion protein (rIX-FP) in previously treated pediatric patients with hemophilia\u00a0B: results from a phase\u00a03b extension study. Thromb Haemost. 2020;120(4):599\u2013606.","journal-title":"Thromb Haemost"},{"issue":"4","key":"3336_CR17","first-page":"659","volume":"116","author":"G Kenet","year":"2016","unstructured":"Kenet G, Chambost H, Male C, et al. Long-acting recombinant fusion protein linking coagulation factor\u00a0IX with albumin (rIX-FP) in children. Results of a phase\u00a03 trial. Thromb Haemost. 2016;116(4):659\u201368.","journal-title":"Thromb Haemost"},{"issue":"1","key":"3336_CR18","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1097\/MBC.0000000000000969","volume":"32","author":"D Lillicrap","year":"2021","unstructured":"Lillicrap D. Evaluating the potential benefits of the extravascular pool of factor\u00a0IX. Blood Coagul Fibrinolysis. 2021;32(1):68\u20139.","journal-title":"Blood Coagul Fibrinolysis"},{"issue":"9","key":"3336_CR19","doi-asserted-by":"publisher","first-page":"3770","DOI":"10.1007\/s12325-023-02559-1","volume":"40","author":"E Funding","year":"2023","unstructured":"Funding E, Lowe G, Poulsen LH, et al. Real-world effectiveness of rFIXFc prophylaxis in patients with haemophilia\u00a0B switched from standard half-life therapy in three European countries. Adv Ther. 2023;40(9):3770\u201383.","journal-title":"Adv Ther"},{"issue":"3","key":"3336_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/j.rpth.2023.100106","volume":"7","author":"A Iorio","year":"2023","unstructured":"Iorio A, MacDonald V, Caillaud A, et al. Treatment switch to nonacog beta pegol factor\u00a0IX in hemophilia\u00a0B: a Canadian cost-consequence analysis based on real-world factor\u00a0IX consumption and clinical outcomes. Res Pract Thromb Haemost. 2023;7(3):100106.","journal-title":"Res Pract Thromb Haemost"},{"issue":"6","key":"3336_CR21","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1111\/hae.14152","volume":"26","author":"A Shapiro","year":"2020","unstructured":"Shapiro A, Chaudhury A, Wang M, et al. Real-world data demonstrate improved bleed control and extended dosing intervals for patients with haemophilia\u00a0B after switching to recombinant factor\u00a0IX Fc fusion protein (rFIXFc) for up to 5\u00a0years. Haemophilia. 2020;26(6):975\u201383.","journal-title":"Haemophilia"},{"issue":"5","key":"3336_CR22","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1055\/s-0036-1571315","volume":"42","author":"E Berntorp","year":"2016","unstructured":"Berntorp E, Andersson NG. Prophylaxis for hemophilia in the era of extended half-life factor VIII\/factor\u00a0IX products. Semin Thromb Hemost. 2016;42(5):518\u201325.","journal-title":"Semin Thromb Hemost"},{"issue":"sup1","key":"3336_CR23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/17474086.2018.1564032","volume":"12","author":"M Escobar","year":"2019","unstructured":"Escobar M, Santagostino E, Mancuso ME, et al. Switching patients in the age of long-acting recombinant products? Expert Rev Hematol. 2019;12(sup1):1\u201313.","journal-title":"Expert Rev Hematol"},{"issue":"7","key":"3336_CR24","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1080\/03007995.2022.2062180","volume":"38","author":"M Olivieri","year":"2022","unstructured":"Olivieri M, Simpson M, Yan S, et al. Analysis of pooled real-world data from Germany, Italy, and the United States of rVIII-singlechain compared with standard- and long-acting FVIII products for prophylaxis of hemophilia A. Curr Med Res Opin. 2022;38(7):1133\u20139.","journal-title":"Curr Med Res Opin"},{"issue":"4","key":"3336_CR25","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1111\/ejh.13378","volume":"104","author":"M Olivieri","year":"2020","unstructured":"Olivieri M, Sommerer P, Maro G, Yan S. Assessing prophylactic use and clinical outcomes in hemophilia A patients treated with rVIII-singlechain and other common rFVIII products in Germany. Eur J Haematol. 2020;104(4):310\u20137.","journal-title":"Eur J Haematol"},{"issue":"4","key":"3336_CR26","first-page":"504","volume":"26","author":"M Simpson","year":"2020","unstructured":"Simpson M, Desai V, Maro G, Yan S. Comparing factor use and bleed rates in U.S. hemophilia A patients receiving prophylaxis with 3 different long-acting recombinant factor VIII products. J Manag Care Spec Pharm. 2020;26(4):504\u201312.","journal-title":"J Manag Care Spec Pharm"},{"issue":"10","key":"3336_CR27","first-page":"1258","volume":"26","author":"S Yan","year":"2020","unstructured":"Yan S, Maro G, Desai V, Simpson M. A real-world analysis of commonly prescribed FVIII products based on U.S. medical charts: consumption and bleeding outcomes in hemophilia A patients. J Manag Care Spec Pharm. 2020;26(10):1258\u201365.","journal-title":"J Manag Care Spec Pharm"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-025-03336-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-025-03336-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-025-03336-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T13:03:10Z","timestamp":1762261390000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-025-03336-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,18]]},"references-count":27,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["3336"],"URL":"https:\/\/doi.org\/10.1007\/s12325-025-03336-y","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,18]]},"assertion":[{"value":"16 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Martin Olivieri has received grants\/research support from Bayer, Biomarin, Biotest, Takeda, CSL Behring Octapharma, Pfizer, Shire, Roche, Stago and Swedish Orphan Biovitrum, consultancy and speaker fees from Bayer, BioMarin, Biotest, Novo Nordisk, Takeda, CSL Behring, Pfizer, Roche and Swedish Orphan Biovitrum; Songkai Yan, Radovan Tomic, Xiang Zhang, Thomas Linhoff and Douglass Drelich are employees of CSL Behring; Ying Yang and Natalie Jakobs are employees of Adivo Associates; Wolfgang Miesbach received consultation fees from Bayer, BioMarin, Biotest, CSL Behring, Chugai, Freeline, LFB, Novo Nordisk, Octapharma, Pfizer, Regeneron, Roche, Sanofi, Sobi, Takeda\/Shire, uniQure.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"Following institutional review board (IBR) evaluation, the study was determined to be exempt from patient informed consent under category\u00a04 (IBR case name:\u00a0CSL Behring - 2023-168, Patient chart analysis to assess real-world outcomes and utilisation of recombinant FIX products in Germany and Italy\u2014IRB protocol#: [Pro00072842])\u00a0as secondary research for which consent is not required; this applied to all 31 haemophilia treatment centres involved in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}